Document type
ArticleVersion
Accepted versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/173502
New synthetic inhibitors of fatty acid synthase with anticancer activity
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Fatty acid synthase (FASN) is a lipogenic enzyme that is highly expressed in different human cancers. Here we report the development of a new series of polyphenolic compounds 5-30 that have been evaluated for their cytotoxic capacity in SK-Br3 cells, a human breast cancer cell line with high FASN expression. The compounds with an IC50 < 50 M have been tested for their ability to inhibit FASN activity. Among them, derivative 30 blocks the 90% of FASN activity at low concentration (4 M), is highly cytotoxic in a broad panel of tumor cells, induces apoptosis, and blocks the activation of HER2, AKT and ERK pathways. Remarkably, 30 does not activate carnitine palmitoyltransferase-1 (CPT-1) nor induces in mice weight loss, which are the main drawbacks of other previously described FASN inhibitors. Thus, FASN inhibitor 30 may aid the validation of this enzyme as a therapeutic target for the treatment of cancer.
Subject (English)
Citation
Citation
TURRADO, Carlos, et al. New synthetic inhibitors of fatty acid synthase with anticancer activity. Journal of Medicinal Chemistry. 2012. Vol. 55, num. 11, pags. 5013-5023. ISSN 0022-2623. [consulted: 18 of June of 2026]. Available at: https://hdl.handle.net/2445/173502